| Title |
Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/10898530-000000000-00000 |
| Pubmed ID | |
| Authors |
Aaron S. Kesselheim, Margaret R. Stedman, Ellen J. Bubrick, Joshua J. Gagne, Alexander S. Misono, Joy L. Lee, M. Alan Brookhart, Jerry Avorn, William H. Shrank |
| Abstract |
The automatic substitution of bioequivalent generics for brand-name antiepileptic drugs (AEDs) has been linked by anecdotal reports to loss of seizure control. To evaluate studies comparing brand-name and generic AEDs, and determine whether evidence exists of superiority of the brand-name version in maintaining seizure control. English-language human studies identified in searches of MEDLINE, EMBASE and International Pharmaceutical Abstracts (1984 to 2009). Randomized controlled trials (RCTs) and observational studies comparing seizure events or seizure-related outcomes between one brand-name AED and at least one alternative version produced by a distinct manufacturer. We identified 16 articles (9 RCTs, 1 prospective nonrandomized trial, 6 observational studies). We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as 'controlled' and 'uncontrolled'. Seven RCTs were included in the meta-analysis. The aggregate odds ratio (n = 204) was 1.1 (95% CI 0.9, 1.2), indicating no difference in the odds of uncontrolled seizure for patients on generic medications compared with patients on brand-name medications. In contrast, the observational studies identified trends in drug or health services utilization that the authors attributed to changes in seizure control. Although most RCTs were short-term evaluations, the available evidence does not suggest an association between loss of seizure control and generic substitution of at least three types of AEDs. The observational study data may be explained by factors such as undue concern from patients or physicians about the effectiveness of generic AEDs after a recent switch. In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 14% |
| Unknown | 6 | 86% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | <1% |
| Malaysia | 1 | <1% |
| France | 1 | <1% |
| Ireland | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 101 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 16% |
| Student > Bachelor | 13 | 12% |
| Student > Master | 12 | 11% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Postgraduate | 9 | 8% |
| Other | 27 | 25% |
| Unknown | 17 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 15% |
| Agricultural and Biological Sciences | 6 | 6% |
| Economics, Econometrics and Finance | 4 | 4% |
| Business, Management and Accounting | 3 | 3% |
| Other | 12 | 11% |
| Unknown | 22 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 48. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2023.
All research outputs
#870,149
of 25,371,288 outputs
Outputs from Drugs
#69
of 3,464 outputs
Outputs of similar age
#4,770
of 189,075 outputs
Outputs of similar age from Drugs
#21
of 1,461 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,075 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 1,461 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.